Publication | Open Access
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
270
Citations
10
References
2022
Year
In patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo. (Funded by Gilead Sciences; CAPELLA ClinicalTrials.gov number, NCT04150068.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1